Member Info for Muck165

Not a suckers share, just an undervalued one presenting a great opportunity for those willing and capable of using their own brain instead of an artificial one.

Surely news on whether we have, or have not, paid Alpha is price sensitive yet no RNS. Have to question the Nomad here I think.

Me neither. Do you know why companies change Nomad/Broker?

I agree we all own a little bit less of ABDX as a result of the issue. But we didn't issue at a discount and so assuming the price we paid is correct, we all own a little bit less of a company that is now worth a little bit more.

The fact IVDeology is currently loss making is neither here nor there.

Our shareholdings have been diluted. Our value has not.

Hi Peter

What I was trying to say was that our value hasn't been diluted, assuming the valuation is correct.

Had we raised to acquire in cash, at an inevitable discount given current capital markets, then more shares would have been issued to obtain the same value.

Another couple of thoughts…

ABDX must see reg support as a growth area, and I wonder if this stems from being unable to cope with all work opportunities in house given current resource.

We’ve waived up to £500k in fees re the FOFH deal, and have now made an acquisition. Doesn’t suggest Yates has concerns about H2 revenue or cash position. Remember, at the investor presentation he was clear H2 this year will beat H2 last year (£2.9m), and in fact they are aiming for a material increase.

Yep. It strengthens our full service offering in an area all developers must go through but few understand or, I suspect, have the aptitude or desire to do themselves. And as is pointed out in the RNS, the whole reg environment here and in the US is going through significant overhaul at the mo.

Initial thoughts are;

-Non dilutive acquisition

-Little integration friction given current owners will continue to run it as a subsid, and because of its small size and employee base (2 employees recorded in last years accounts).

-Bolsters our regulatory support and provides us with a U.K. Responsible Person

-No impact on cash.

- Wouldn’t sell for ABDX paper unless they had confidence in ABDX growth

- U.K. market is often first in commercial roll out because UKCA seems less difficult to get, which is attractive to non U.K. and particularly US developers (who also need a U.K. responsible person). Boosting expertise should therefore help with international customer base and pipeline opportunities.

- Should wipe its face based on current revenues, but would expect workloads/revenue to increase through ABDX customers, contacts and pipeline.

I think this is a great acquisition.

Perhaps just a little observation, but we know Salignostics have been progressing FDA approval for Salistick for nearly three years now, that they are currently "positioning" the product in the States, and that Salistick made Time Magazine's top 200 inventions of 2023.

Well today Time published its top 100 most influential people in Health and included Raluca Cohen, one of the scientist behind Salistick, in this list.

Can't hurt in the US positioning....

https://time.com/collection/time100-health/

https://time.com/6962679/raluca-cohen/

A little more here

https://neutrapharma.com/products/home-self-test-kits/

Interesting post from Neutrapharma today, introducing their “exclusive collaboration” with us to distribute our AST range.

To be honest I don’t think this agreement is new. What is a little more interesting is that they say 2 new tests will be launched this summer. Perhaps the FOFH STI tests?

https://www.linkedin.com/posts/neutrapharma-europe-limited_exclusive-pharmacy-pharmacist-activity-7191728649132204033-_xu5?utm_source=share&utm_medium=member_desktop

Looks like Loop are in the middle of another funding round, seeking £5m with 15% intended for U.K. launch. Some interesting info in this pitch slide.

https://www.linkedin.com/posts/choskin-exec-leader_techtuesday-innovation-investor-activity-7191028516694466561-l55L?utm_source=share&utm_medium=member_desktop

I really hope not. Growing through acquisition always sounds great but the reality in my experience is that integration frictions and costs are underestimated. And I agree, it’s unlikely we could afford it anyway.

Agree RCMP. Alpha out of patience. No diamonds. Uncertain refi option which even if secured only covers Alpha to “a large extent”. First $1.5m payment due next Tuesday. Baita production constrained by lack of money. No PGM sales because of concentrate variability.

Even the fluff in this RNS seems less fluffy! Lipstick on a pig. Real risk of a raise imminently.

I’m afraid to say the Boots tie up might not be as lucrative as I’d thought.

If you look through this Amazon listing for the AST Vit D test you will see it originates from China and is made by ( Hangzhou) AllTest. That is the same manufacturer for all other AST tests listed on Amazon, as well as being the manufacturer for all MHC lateral flow tests.

So if you buy a Boots, AST, or MHC lateral flow test, I think the reality is it will be precisely the same test in the box, ie a Chinese AllTest.

That perhaps explains the involvement of Crest Medical. I suspect we are an authorised AllTest distributor with rights to brand, that Crest are a Boots supplier, that Crest have sourced the tests from us for supply to Boots, and that we have assisted in their re-branding. That would tie up much more with what Yates said in the investor presentation.

We will still of course be getting a cut from all “Boots” tests sold, just not as much as I’d thought. The bigger value lies in having created the relationship such that future tests we may make, like the FOFH tests, could find their way onto Boots shelves.

Others may well have twigged this long before I have, I just assumed we made the AST tests - feel a bit of an idiot to be honest.

https://www.amazon.co.uk/Abingdon-Simply-Test-Vitamin-Test/dp/B0BXM3QTRD?ref_=ast_sto_dp

Another little one…

Whatever own brand Vitamin D stock Boots bought has sold out online. “New stock coming soon”. We don’t know, of course, how much they bought initially, but it’s still a good sign I think.

We’re on the same page TD. Likely more delay, but no indication of JV collapse.

Perhaps. But equally they’d be idiots, I think, to say it’s imminent if they had any concerns whatsoever.

GRV published its quarterly report overnight.

Re EP145 they say “Ministerial consent is expected imminently”

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02799530-2A1519561

Just a bit of a throw away observation, but I did notice in the FOFH RNS that ABDX highlighted they will have rights to offer the STI tests as own brand retailer products, and you have to wonder if they have Boots in mind. Whatever the case, its clear that retailer own branding is something ABDX are pursuing and, of course, we can offer exactly the same test ( I think) to multiple retailers as an own brand product.